More mutation accumulation in Neisseria gonorrhoeae(NG)with susceptibility than that in NG with decreased susceptibility to ceftriaxone  

作　　者：Jing-Yao Liang Yi-Qi Jiang Wen-Ling Cao Xiao-Dong Li Dong-Mei Li Jian-Qin Wang Si-Long Sun Xi-Bao Zhang 

机构地区：[1]Institute of Dermatology,Guangzhou Medical University,Guangzhou,Guangdong 510095,China [2]BGI Genomics,BGI-Shenzhen,Shenzhen,Guangdong 518083,China [3]Department of Dermatology,Guangzhou Institute of Dermatology,Guangzhou,Guangdong 510095,China [4]Department of Microbiology and Immunology,Georgetown University Medical Center,Washington,DC,USA

出　　处：《Chinese Medical Journal》2020年第13期1623-1625,共3页中华医学杂志（英文版）

基　　金：This study was supported by grants from the Natural Science Foundation of Guangdong(No.2018A0303130011);the Medical and Health Technology Projects of Guangzhou(No.20171A011284);and the Medical Science and Technology Research Foundation of Guangdong Province(No.A2017239).

摘　　要：To the Editor:Neisseria gonorrboeae(NG)with decreased susceptibility to ceftriaxone(CRO)and cefixime,the last option for first-line anti-microbial monotherapy,was spread globally.Until now,more than ten clinical treatment failures with CRO have been reported with minimum inhibitory concentration(MIC)range as 0.5 to 2.0 mg/L.CRO,thereafter,is no longer recommended as mono-therapy for gonorrhea.Instead,dual therapy that combines CRO with azithromycin is currently exerted in many countries including China.However,the first treatment failure to dual therapy(500 mg CRO plus 1 g azithromycin)was identifed in 2014 in London.

关 键 词：SUSCEPTIBILITY treatment globally 

分 类 号：R759.2[医药卫生—皮肤病学与性病学]